OPERATIONAL GUIDELINES
for Hepatitis B Vaccine in the
Universal Immunization Programme

Ministry of Health & Family Welfare
Government of India
2009
OPERATIONAL GUIDELINES
for Hepatitis B Vaccine in the
Universal Immunization Programme

Ministry of Health & Family Welfare
Government of India
2009
Suggestions for improving or enhancing the Operational Guidelines for Hepatitis B vaccine in the Universal Immunization Programme are always welcome and encouraged.
# Table of Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abbreviations</td>
<td>I</td>
</tr>
<tr>
<td>Target Audience</td>
<td>V</td>
</tr>
<tr>
<td><strong>HEPATITIS B DISEASE AND VACCINE</strong></td>
<td></td>
</tr>
<tr>
<td>Background</td>
<td>3</td>
</tr>
<tr>
<td>The Hepatitis B Virus</td>
<td>5</td>
</tr>
<tr>
<td>Modes of Transmission</td>
<td>7</td>
</tr>
<tr>
<td>Clinical Features</td>
<td>8</td>
</tr>
<tr>
<td>The Hepatitis B Vaccine</td>
<td>11</td>
</tr>
<tr>
<td>Vaccination Schedule</td>
<td>12</td>
</tr>
<tr>
<td>Storage Temperature</td>
<td>15</td>
</tr>
<tr>
<td>Safety of Hepatitis B Vaccine</td>
<td>16</td>
</tr>
<tr>
<td>Injection Technique and Safety</td>
<td>18</td>
</tr>
<tr>
<td>Adverse Events Following Immunization</td>
<td>22</td>
</tr>
<tr>
<td><strong>HEPATITIS B VACCINATION IN INDIA</strong></td>
<td></td>
</tr>
<tr>
<td>Introduction and Progress</td>
<td>27</td>
</tr>
<tr>
<td>Objectives and Strategies</td>
<td>29</td>
</tr>
<tr>
<td><strong>INCLUSION OF HEPATITIS B VACCINE IN THE UIP</strong></td>
<td></td>
</tr>
<tr>
<td>Planning for the Inclusion of Hepatitis B Vaccine</td>
<td>33</td>
</tr>
<tr>
<td>1. Estimate Beneficiaries and Sessions</td>
<td>35</td>
</tr>
<tr>
<td>2. Estimate Vaccine Needs</td>
<td>37</td>
</tr>
<tr>
<td>3. Estimate Syringe Needs</td>
<td>39</td>
</tr>
<tr>
<td>4. Estimate Storage Needs</td>
<td>40</td>
</tr>
<tr>
<td>5. Manage Cold Chain</td>
<td>42</td>
</tr>
<tr>
<td>6. Minimize Vaccine Wastage</td>
<td>49</td>
</tr>
<tr>
<td>7. Update Recording and Reporting Systems</td>
<td>50</td>
</tr>
<tr>
<td>8. Prepare and Train Staff</td>
<td>52</td>
</tr>
<tr>
<td>9. Plan Advocacy &amp; Social Mobilization</td>
<td>57</td>
</tr>
<tr>
<td>10. Supervise, Monitor and Evaluate</td>
<td>64</td>
</tr>
<tr>
<td><strong>ANNEXURES</strong></td>
<td>73-94</td>
</tr>
</tbody>
</table>
Abbreviations

ADS        Auto Disable Syringe
AEFI       Adverse Events Following Immunization
ASHA       Accredited Social Health activist
AWW        Aanganwadi Worker
CHC        Community Health Centre
DNA        Deoxyribonucleic acid
DPT        Diphtheria, Pertussis, Tetanus Vaccine
DT         Diphtheria, Tetanus Vaccine
EPI        Expanded Program on Immunization
GAVI       Global Alliance for Vaccines and Immunization
GoI        Government of India
HBcAg      Hepatitis B Core Antigen
HBeAg      Hepatitis B e antigen
HBsAg      Hepatitis B Surface Antigen
HBV        Hepatitis B Virus
Hib        Haemophilus Influenzae type b
HIV        Human Immunodeficiency Virus
ILR        Ice Lined Refrigerator
IPC        Interpersonal Communication
NGO        Non Governmental Organization
OPV        Oral Polio Vaccine
PHC        Primary Health Centre
TT         Tetanus Toxoid
UIP        Universal Immunization Programme
UNICEF     United Nations’ Children’s Fund
VVM        Vaccine Vial Monitor
WHO        World Health Organization
These guidelines are meant to assist immunization programme managers at state, district and sub-district levels in introducing the hepatitis B vaccine into their immunization programmes. The intention is to provide information that is practical as well as technically and operationally sound.
HEPATITIS B DISEASE AND VACCINE
Hepatitis B is a major public health problem worldwide. Approximately 30% of the world's population, or about 200 crore (2 billion) persons, are estimated to be infected with Hepatitis B Virus (HBV). Of these, an estimated 35 crore (350 million) have chronic HBV infection and are at the risk of serious illness and death from cirrhosis and liver cancer; diseases that are estimated to cause about 5,00,000 - 7,00,000 deaths each year worldwide.

Safe and effective vaccine is available against hepatitis B since 1982. The World Health Organization (WHO) recommends that routine vaccination of all infants against HBV infection should become an integral part of national immunization schedules worldwide. High coverage with the primary vaccine series among infants has the greatest impact on the prevalence of chronic HBV infection in children.

In the fourteenth meeting of Global Advisory Group (GAG) on Expanded Program on Immunization (EPI) 1991, it was decided that hepatitis B vaccine should be an integral part of national immunization programmes worldwide by 1997 and this decision was reaffirmed in the 45th World Health Assembly (1992). As of August 2008, 169 countries have fully included and 2 countries have partially included this vaccine in their national immunization programmes. In countries that have implemented universal childhood hepatitis B vaccination, chronic HBV infection and incidence rates of long-term complications like liver cancer have declined markedly.
In India, the available data indicate that the country has intermediate endemicity of hepatitis B, with prevalence of Hepatitis B Surface Antigen (HBsAg) between 2% and 10% among several populations studied. The number of HBsAg carriers in India has been estimated to be over 4 crore (40 million). About 15-25% of HBsAg carriers are likely to suffer from cirrhosis and liver cancer and may die prematurely. Infections occurring during infancy and childhood have the greatest risk of becoming chronic. Of the 2.6 crore (26 million) infants born every year in India, approximately 10 lakh (1 million) run the life-time risk of developing chronic HBV infection. The hepatitis B vaccine, as part of the Universal Immunization Programme (UIP), would prevent these chronic infections, and hence Government of India is including the vaccine in the UIP.
HBV is a 42nm partially double stranded DNA virus, belonging to the family Hepadnaviridae, and is composed of a nucleocapsid core (core antigen or HBcAg), surrounded by an outer lipoprotein coat (surface antigen or HBsAg). Surface antigen (HBsAG) is produced in vast excess and is found in the blood of the infected person as filamentous or spherical particles (without core) having a mean diameter of 22nm. During rapid replication a core related protein (e antigen or HBeAg) is produced not incorporated into the virion but secreted out into the serum. HBV is found in all body fluids. HBV-related acute and chronic liver disease is one of the major causes of infectious disease-related mortality worldwide.

**Humans are the only known natural host for HBV**, although some non-human primates have been infected in laboratory conditions. HBV is relatively resilient and, in some instances, has been shown to remain infectious on environmental surfaces for about a week at room temperature.
HBV contains numerous antigenic components, including surface antigen on the lipoprotein coat (HBsAg), Hepatitis B core antigen (HBcAg), and Hepatitis B e antigen (HBeAg).

Several well-defined antigen-antibody systems are associated with HBV infection as shown in the table below.

<table>
<thead>
<tr>
<th>Antigen or Antibody</th>
<th>Presence in serum</th>
<th>Inference</th>
</tr>
</thead>
<tbody>
<tr>
<td>HBsAg (Australia antigen, Surface antigen on the outer lipoprotein coat)</td>
<td>Yes, 30-60 days after exposure</td>
<td>Infection and infectivity</td>
</tr>
<tr>
<td>HBcAg (Core antigen)</td>
<td>Difficult to detect. Detected in the liver tissue with Acute or chronic infection</td>
<td>Infection</td>
</tr>
<tr>
<td>HBeAg (Core related protein that is secreted out into serum)</td>
<td>Yes, with high virus titres and during rapid replication of virus</td>
<td>High infectivity</td>
</tr>
<tr>
<td>Anti-HBs</td>
<td>Yes, during convalescence after Acute infection or following HepB vaccination</td>
<td>Immunity to HBV</td>
</tr>
<tr>
<td>IgM anti-HBc</td>
<td>Yes</td>
<td>Recent infection</td>
</tr>
<tr>
<td>Total Anti-HBc</td>
<td>Yes</td>
<td>Infection in undefined past</td>
</tr>
<tr>
<td>Anti-HBe</td>
<td>Yes</td>
<td>Low infectivity</td>
</tr>
</tbody>
</table>
HBV is transmitted through contact with infected blood or body fluids across breakages in skin/mucous membranes and unprotected sexual intercourse. HBV is 100 times more infectious than Human Immunodeficiency Virus (HIV). Unlike HIV, HBV is able to remain active on surfaces (e.g. table tops, razor blades, blood stains etc) for about a week without losing infectivity. The primary routes of transmission are:

**Modes of Transmission**

- from mother to baby, usually at the time of birth (perinatal transmission)
- from child to child, (also adult to child). Infected children and most chronically infected adults look healthy. Transmission occurs during play through cuts, bites, scrapes, scratches or contact with wounds.
- through unsafe blood transfusions and organ transplant
- through drug users sharing needles, or through unsafe injections or other unsafe medical procedures
- through unprotected sexual contact

Child to child transmission accounts for most HBV infections
Outcomes of HBV Infection

Hepatitis B disease is the inflammation of the liver cells caused by HBV. The outcomes of HBV infection are age dependent and include acute (short term and clinically apparent) hepatitis B and chronic (long-term and mostly unapparent) disease. The infecting dose of virus and the age of the person infected are important factors that correlate with the severity of acute or chronic hepatitis B. Only a small proportion of acute HBV are actually recognized clinically.

Spectrum of liver diseases following HBV infection

Acute hepatitis B

Acute hepatitis B occurs in approximately 1% of perinatal, 10% of early childhood (1-5 years old) and about 30% late (> 5 years old) HBV infections. The course of acute hepatitis B is extremely variable and the incubation period ranges from 2 to 5 months (average 3 months). Common symptoms include:
- Fever (mild or absent)
- Loss of appetite
- Tiredness
- Pain in muscles, joints
- Nausea, diarrhoea and vomiting
- Pain abdomen
- Headache
- Dark urine
- Pale stools
- Jaundice

Most acute hepatitis cases result in recovery except about 1% of them, progressing to fulminant hepatitis. Fulminant hepatitis has a very high mortality at about 70%.

**Chronic HBV infection**

Chronic HBV infection is one of the most common and persistent viral infections in humans. If infection occurs in infancy, 99% remain asymptomatic. 90% of these become chronic carriers. In contrast, 30% of those infected during childhood (1-5 yrs) and 6% of those infected during adulthood become chronic carriers. Persons with chronic HBV infection have a 15-25% risk of dying prematurely due to HBV related liver cirrhosis and cancer. The example in the table below demonstrates, out of 100 persons infected at different ages, the number of persons at the risk of developing chronic HBV infection and complications.
In Africa and Asia, liver cancer is second only to tobacco as the most frequent cause of cancer deaths among adult males, most of which are attributed to HBV infection.

### Diagnosis

It is not possible, on clinical grounds, to differentiate hepatitis B from hepatitis caused by other viral agents. Diagnosis of hepatitis B is confirmed by demonstration of specific antigens and/or antibodies in the patient's serum.

#### Acute HBV infection:
- Presence of HBsAg (surface antigen) and IgM antibody against core antigen (IgM anti-HBc)
- Presence of HBeAg (hepatitis B e antigen) during the initial, highly replicative phase of infection. HBeAg indicates high infectivity.
- Appearance of Antibody (after several weeks of infection) to HBsAg (Anti-HBs) and disappearance of HBsAg signals recovery.

#### Chronic HBV Infection:
- Persistence of HBsAg for more than 6 months is characteristic
- with or without HBeAg (Presence of HBeAg infers high infectivity)

### Marker of HBV infection:
Total Anti-HBc in serum indicates HBV infection current, or past.

<table>
<thead>
<tr>
<th>Type</th>
<th>IF Infected</th>
<th>THEN chronic HBV infection</th>
<th>AND Cirrhosis/ Carcinoma*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infant</td>
<td>100</td>
<td>90% = 90</td>
<td>15% of 90 = 14</td>
</tr>
<tr>
<td>Child(1-5yrs)</td>
<td>100</td>
<td>30% = 30</td>
<td>15% of 30 = 5</td>
</tr>
<tr>
<td>Adult</td>
<td>100</td>
<td>6% = 6</td>
<td>15% of 6 = 1</td>
</tr>
</tbody>
</table>

*assuming the lower rate of 15% complications
The hepatitis B vaccine is the **first vaccine against a cancer** (primary liver cancer). Safe and effective, the vaccine has been available commercially since 1982. Hepatitis B vaccines are available as:

- Monovalent, and
- Combination (DPT-HepB, DPT-HepB+ Hib, and HepB-Hib etc)

The currently used hepatitis B vaccines in UIP are prepared by using the HBsAg grown in yeast cells by DNA recombinant technology. The vaccine contains only the 22nm non-infectious surface antigen (HBsAg) particles and not the entire virus. It does not contain any live components, reducing chances of vaccine-induced complications. It however contains alum as adjuvant and may contain thiomersal used as a preservative in multi-dose preparations.

The completed vaccination series induces protective antibody levels in about 95% of infants, in a variety of vaccination schedules.

When countries include hepatitis B vaccine as part of routine childhood immunization programmes, following sustained high coverage, HBV infection in children is essentially eliminated in 10 to 15 years resulting in significant reduction in long term complications of HBV infection such as cirrhosis and liver cancer later.
Vaccination Schedule

Hepatitis B vaccine schedule

Current immunization schedule for hepatitis B vaccine includes a Birth dose given as early as possible after birth preferably within 24 hours for all institutional deliveries. Irrespective of the Birth dose, 3 doses are to be given at 6, 10, 14 weeks at the same time as DPT and OPV.

Vaccination Schedule:

<table>
<thead>
<tr>
<th>Age</th>
<th>Vaccines</th>
</tr>
</thead>
<tbody>
<tr>
<td>Birth</td>
<td>HepB0</td>
</tr>
<tr>
<td></td>
<td>BCG</td>
</tr>
<tr>
<td></td>
<td>OPV0</td>
</tr>
<tr>
<td>6 weeks</td>
<td>HepB1</td>
</tr>
<tr>
<td></td>
<td>DPT1</td>
</tr>
<tr>
<td></td>
<td>OPV1</td>
</tr>
<tr>
<td>10 weeks</td>
<td>HepB2</td>
</tr>
<tr>
<td></td>
<td>DPT2</td>
</tr>
<tr>
<td></td>
<td>OPV2</td>
</tr>
<tr>
<td>14 weeks</td>
<td>HepB3</td>
</tr>
<tr>
<td></td>
<td>DPT3</td>
</tr>
<tr>
<td></td>
<td>OPV3</td>
</tr>
</tbody>
</table>

Target Age Group

Infants run the highest risk of developing chronic hepatitis B (90%) following infection by HBV. This risk decreases significantly with age. Therefore, infants should be immunized before they are exposed to HBV infection preferably at birth. Accordingly, the Government of India (GoI) has decided to adopt the strategy to administer a dose of hepatitis B vaccine as early as possible after birth preferably within in 24 hours for all institutional deliveries and further three doses.
given at the same time as DPT in the prospective birth cohort\(^1\) of children below the age of one year.

**Dosage**

The standard paediatric dose of the hepatitis B vaccines (Monovalent hepatitis B vaccine and combinations) is 0.5ml. It is a cloudy liquid that is available in a 10 dose vial and does not require reconstitution. If the vaccine is allowed to stand for a long time, it separates from the liquid and looks like fine sand at the bottom of the vial. The vaccine must be mixed by rolling the vial gently between the hands.

**Long-Term Protection and Booster Doses**

Protection afforded by the hepatitis B vaccine is at least 15 years and based on the current scientific evidence it lasts lifelong. Even if the antibodies wane in the serum, long-term protection relies on immunological memory, allowing a protective anamnestic antibody response (memory response of the body to produce antibodies with the help of memory B cells and memory T4 cells) after exposure to HBV or vaccine. **Booster doses are, therefore, not recommended during childhood** vaccination after the age of 1 year.

---

\(^1\) The new birth cohort who presents for first dose of DPT.
All due vaccines can be given at same time but in different sites e.g. it is safe and effective to give BCG, OPV, DPT, HepB, Measles & VitA at same time to a 9 month completed child who has never been immunized.
The storage temperature for hepatitis B vaccine is the same as for DPT vaccine, i.e. between +2 °C and +8 °C. The vaccine is generally heat-stable but is highly freeze-sensitive and **MUST NOT BE FROZEN**. The freezing point of hepatitis B vaccine is about -0.5 °C. The freezing of the vaccine causes the HBsAg protein to dissociate from the alum adjuvant and thus to lose its immunogenicity/potency.
Safety of Hepatitis B Vaccine

Hepatitis B vaccine is a very safe vaccine with proven efficacy. Since 1982, over 100 crore (1 billion) doses of hepatitis B vaccine have been used worldwide. The rates of mild fever and/or irritability following simultaneous vaccination of children by hepatitis B and DPT vaccines is similar as when DPT vaccine is administered alone.

Mild transient side effects:
Most common side effect is pain at the injection site. Mild systemic complaints like fatigue, headache, irritability and fever higher than 37.7 °C which may usually start within a day after the vaccination and may last for one to two days.

Serious allergic (anaphylactic) reactions:
Serious allergic reactions to the vaccine are rare at about 1-2 per 10 lakh (1 million) doses and may include: generalized urticaria, difficulty in breathing, swelling of the mouth and throat, hypotension, shock

Contraindications
The only two absolute contraindications to withhold or postpone the administration of the hepatitis B vaccine are:

- A severe allergic reaction to a vaccine component or following a prior dose of hepatitis B vaccine. Such allergic reactions are rare. Further doses are contraindicated if there is a history of anaphylaxis to a previous dose.
- **Persons with moderate or severe acute illness** should not be vaccinated until their condition improves. However, a minor illness, such as an upper respiratory infection, is not a contraindication to vaccination.

**The following are NOT contraindications**

- Minor illness, such as respiratory tract infection or diarrhoea with temperature below 38.5 °C
- Asthma
- Prematurity or low birth weight
- History of jaundice at birth
- Treatment with antibiotics
- Infection with HIV
- History of seizures (convulsions, fits)
- Diseases of the heart, lung, kidney or liver
- Congenital anomalies
- Neurological conditions such as cerebral palsy and Down’s syndrome
Like the DPT vaccine, the hepatitis B vaccine is given intramuscularly on the antero-lateral aspect of the mid-thigh (vastus lateralis muscle). Both the vaccines can be administered simultaneously, although at different sites. That is, if DPT is injected in the left thigh of the infant, then hepatitis B vaccine can be given on the right thigh, at the same time.

**Injection Technique and Safety**

Stretch skin flat between finger and thumb on both sides at outer Mid-thigh (Antero-lateral aspect) keeping needle at 90° to surface

**Giving the vaccine: DOs**

- Divide the thigh into three equal parts from the knee to the hip.
- Clean the skin, if dirty, with a clean water swab and let it dry.
- Place your thumb and index finger on each side of the place where you intend to inject and stretch the skin slightly.
- Push the needle at a 90° angle deep into the muscle.
- Press the top of the plunger with your thumb to inject the vaccine and withdraw the needle.
**Giving the vaccine: DON'Ts**

- DO NOT give hepatitis B vaccine in the buttock as this route of administration has been associated with decreased protective antibody levels, because of injection into subcutaneous fat. In addition there may be a risk of injury to the sciatic nerve.

- DO NOT administer hepatitis B vaccine intra-dermally because this route of administration does not produce an adequate antibody response in children.

- DO NOT mix hepatitis B vaccine in the same syringe with other vaccines.

**Follow safe injection and Waste Disposal practices**

Injection safety should be followed meticulously for each injection given and waste should be disposed carefully to prevent damage to self and others.

- **For safety, use Auto Disable Syringes (ADS) supplied by Government of India and not any other Disposable syringes/ needles or Glass syringes**
• Follow GOI - Central Pollution Control Board (CPCB) guidelines

• Keep hands clean before giving injections
  o Wash or disinfect hands prior to preparing injection material.
  o Cover any small cuts on the service provider's skin. Wear sterile gloves to cover if possible.

• Use sterile injection equipment, every time

• Prevent the contamination of vaccine and injection equipment
  o Prepare each injection in a designated clean area where contamination from blood or body fluid is unlikely.
  o If the injection site is dirty, wash with clean water swab
  o Always pierce the rubber cap of the vial with a sterile needle.
  o Do not leave the needle in the stopper of the vial.
  o Follow product-specific recommendations for use, storage, and handling of a vaccine.
  o Discard any needle that has touched any non-sterile surface.

• Assume all used equipment is contaminated
  o Always cut the used syringe at the hub immediately after use using the hub cutter provided for the purpose.
o Do not keep used syringes lying on the table or throw carelessly into a dust bin
o Never try to recap or bend the needle of the syringe

- **Practice safe disposal of all medical sharps waste**
  o Used sharps (needles) are cut and deposited in a hub cutter and then carried to the PHC for safe disposal.
  o AT PHC disinfect sharps in an autoclave or by boiling in water for at least 10 minutes or by chemical method (1% hypochlorite solution for 30 min)
  o Treated sharps are to be disposed in safety pit
  o Disinfect the plastic portion of the syringes and send for recycling
  o Alternately send all collected material for safe disposal at the Common Bio-medical Waste Treatment Facility (CBWTF) if such facility is available

- **Prevent needle-stick injuries**
  o Do not recap.
  o Collect sharps in a puncture proof container (Hub cutter).
  o Anticipate sudden movement of the child.

<table>
<thead>
<tr>
<th>Safe immunization practices</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><img src="image1.png" alt="Image" /></td>
</tr>
<tr>
<td>Do not recap the needle</td>
<td><img src="image2.png" alt="Image" /></td>
</tr>
<tr>
<td>Do not leave the needle inside the vial</td>
<td><img src="image3.png" alt="Image" /></td>
</tr>
<tr>
<td>Do not touch the needle</td>
<td><img src="image4.png" alt="Image" /></td>
</tr>
</tbody>
</table>
An AEFI is a medical incident that takes place after an immunization, causes concern and is believed to be caused by the immunization. Hepatitis B vaccine is a very safe vaccine and AEFIs are extremely rare. However all suspected AEFIs must be reported as per the national AEFI surveillance guidelines.

**Management of AEFI**

Although extremely rare, the health system has to be prepared for managing these serious AEFI. AEFI management for hepatitis B vaccine is similar to that of other vaccines in the immunization schedule.

When parents bring a child with complaints after the immunization,

- Please listen patiently.
- Do not ignore them.
- Do not panic and please attend to the patient immediately
- Keep the child under observation
Initiate action as per suggested guidelines stated below:

**A. Redness and swelling at the site of injection** - cold compress

**B. Fever and pain at the site of injection**
Give Paracetamol, 10-15mg/Kg body weight.
(The Paracetamol syrup contains 125mg per 5ml and can also be prescribed for infants)

**C. Anaphylactic Reaction**
Refer to Annexure 10 for Guidelines on Recognition and Management of Anaphylaxis.

Any presumed risk of serious adverse events associated with hepatitis B vaccine (1-2 cases per 10 lakh doses) must be balanced with the expected 4,000 to 5,000 HBV-related serious liver diseases such as cirrhosis and cancer that would occur in the same population without immunization, assuming a 5% lifetime risk of HBV infection and a 15% long term serious liver diseases among the chronically infected.
Limitations

In order to maintain public trust in the vaccine, it needs to be clarified that, although more than 95% infants develop antibodies with full course of vaccination. A small percentage who do not develop antibodies may still remain vulnerable to hepatitis B. Also it is important to clarify that hepatitis B vaccine protects only against hepatitis B; it does not protect against other types of hepatitis or jaundice. Hence jaundice may still occur due to infection from other hepatitis viruses or other causes such as haemolysis and obstruction to the bile flow.
HEPATITIS B VACCINATION IN INDIA
Several analyses indicate that the inclusion of hepatitis B vaccine in the universal immunization programme is highly cost-effective, even in areas with low HBV endemicity. India has intermediate endemicity of hepatitis B with prevalence of HBsAg between 2% and 10% among several populations studied.

Following the advocacy for inclusion of the hepatitis B vaccine in the immunization schedule by the Indian Academy of Paediatrics, the vaccine has been available in the private sector in India for the last few years. The GoI introduced the hepatitis B vaccine in 2002-03, as a pilot in 33 districts and 14 cities. With the success of the pilot the programme was expanded in 2007-08 to 10 selected states with better UIP performance. GOI plans to cover the rest of the country in a phased manner.
Objectives and Strategies

The long term goal of including hepatitis B vaccination in the UIP is to reduce morbidity and mortality associated with chronic HBV infection, including cirrhosis and liver cancer. However, because the long-term consequences of HBV infection occur several years after infection, this goal will take a long time to attain. Therefore, the following short-term goals and objectives have been defined:

- Delivery of hepatitis B vaccine along with all other EPI vaccines according to safe injection practices.
- Training of health care workers, and sensitisation of policy makers and the community about HBV infection and hepatitis B vaccine.
- Utilising introduction of hepatitis B vaccine as an opportunity to increase attention and action on improving the monitoring of cold chain, injection safety and proper disposal of medical waste including AD syringes.
INCLUSION OF HEPATITIS B VACCINE IN THE UIP
Planning for the Inclusion of Hepatitis B Vaccine

Inclusion of hepatitis B vaccine into the routine immunization schedule requires careful planning at all levels. This initially involves top-down macro-planning at the state level. Later on, with micro-planning, precise logistics and financial needs for each district and sub-district levels are calculated bottom-up, i.e., starting from the more peripheral levels and moving towards the higher levels.

**Macro-planning (at State Level)**

This includes the following elements:

- seek commitment and support for introduction of hepatitis B from various departments and stakeholders
- develop social mobilization activities
- prepare a training plan
- develop and disseminate immunization guidelines (e.g. injection safety, cold chain, AEFI)
- develop plans for supervision, monitoring and evaluation, including providing of feedback.

**Micro-planning (at District, Sub-district levels)**

This includes the following elements:

- use the prescribed formats for UIP micro-planning spreadsheets at each level
- evaluate the availability and ensure adequate cold chain space at all levels
- calculate vaccine and logistics at each level
- develop the final operational plan, including budget
- order and ensure delivery of all materials needed to introduce the vaccine
- modify and disseminate revised reporting, recording format and immunization card etc
- undertake training of health workers and staff at all levels
- implement social mobilization activities around the introduction of the new vaccine.

More generally, programme managers at all levels need to undertake the following activities, which will be described in some detail in the following sections.

1. estimate beneficiaries and sessions
2. estimate vaccine needs
3. estimate syringe needs
4. estimate storage needs
5. manage cold chain
6. minimize vaccine wastage
7. update recording and reporting systems
8. prepare and train staff
9. plan advocacy and social mobilization including IEC.
10. supervise, monitor, evaluate and provide feedback.
1. Estimate Beneficiaries and Sessions

The inclusion of hepatitis B vaccine into UIP will result in an increase in the number of injections and the workload at the immunization sessions. In this section, we learn to calculate the additional number of injections, with the introduction of this new vaccine in the schedule. Estimate beneficiaries *(Actual surveyed as per Community Need Assessment-CNA or if that is not available estimation based on population and indicators such as birth rate and Infant Mortality Rate-IMR)* using the same figures of infants as used in the UIP planning. Calculate the total number of injections required to be given under UIP, including hepatitis B vaccine for the estimated number of beneficiaries. Now calculate the number of sessions required based on the injection load, according to the guidelines (as given below). Then, make the resultant changes in the existing micro-plans, considering the additional injection load of hepatitis B vaccine. Make a workable micro-plan suitable to local conditions and staff availability.

**Outreach sites**

- For every 25-50 injections, plan one session a month.
- If more than 50 injections are expected, then plan two sessions a month.
- If less than 25 injections are expected, then plan a session for every alternate month or once in three months.
- However ensure that, a minimum of 4 sessions are held in a year.
Fixed sites (PHC/CHC/Referral Hospitals)

- Number of sessions at fixed sites (PHC/CHC/Referral Hospitals) should be planned based on workload to suit local conditions. Avoid overcrowding and plan daily sessions at busy sites if needed.
2. Estimate Vaccine Needs

**Why forecast?**
- Accurate forecasting is essential to ensure that the right amount of vaccines, injection and cold chain equipment are available to vaccinate all eligible infants at a given time in a given area.
- Efficient forecasting allows for efficient management of logistics, proper schedule of delivery in manageable quantities and efficient immunization services.
- Furthermore, it ensures an adequate buffer stock to meet unexpected needs.

**Wastage rate and wastage factor**
- Wastage rate (expressed in %) is the proportion of vaccine that is wasted due to a variety of reasons (e.g. left over doses in opened vials, wasted unopened vial etc) to that which was used.
- e.g. If 100 doses are used to vaccinate 75 children, then wastage rate is 25%
- Wastage factor is a mathematical derivative used to account for the correct amount needed for an immunization session, taking into account the existing wastage rate.
- E.g. if the wastage rate is 25 %, then the wastage factor is $\frac{100}{(100 - 25)} = 1.33$
- Therefore, if 50 infants are to be vaccinated with 4 doses of hepatitis B, then the vaccine requirement is $50 \times 4 \times 1.33 = 266$ doses

**Buffer stock**
Buffer stock ensures that there is sufficient stock to tide over sudden and unexpected shortages. This is generally 25% of requirement.
The number of hepatitis B vaccine doses required is estimated using the number of target infants, the number of doses in the immunization schedule (i.e. 4), the wastage factor and buffer stock required.

Calculating vaccine requirements

Use the following steps to calculate the total number of doses needed to introduce hepatitis B vaccine.

**Step 1: Calculate the doses administered per year**

\[
\text{Doses administered per year} = \text{Target infants} \times \text{Number of doses per infant}
\]

**Step 2: Calculate the yearly vaccine requirement with wastage**

\[
\text{Total vaccine doses used per year} = \text{Doses administered per year} \times \text{Wastage factor (1.33)}
\]

**Step 3: Calculate the yearly vaccine requirement with buffer stock**

\[
\text{Total vaccine doses needed to introduce vaccine in first year} = \text{Total vaccine doses used per year} \times \text{buffer stock factor (1.25)}
\]

To combine these 3 steps in one formula:

\[
\text{Total vaccine doses needed to introduce vaccine in first year} = \text{Target Infants} \times 4 \times 1.33 \times 1.25
\]

**Case Study 1**

Dr Taiyyar Kumar is the District Immunization Officer of Hariyali District in Van Pradesh where hepatitis B vaccine is to be introduced for the first time. His target infants are 60,000. He calculates vaccine requirements thus:

\[
\text{Total vaccine doses needed to introduce vaccine in first year} = 60,000 \times 4 \times 1.33 \times 1.25 = 399,000 \text{ doses}
\]
3. Estimate Syringe Needs

Use the following steps to estimate the number of syringes needed for introduction of the hepatitis B vaccine.

**Step 1: Calculate the number of injections administered per year**

\[
\text{Injections administered per year} = \text{Target infants} \times \text{Number of doses per infant}
\]

**Step 2: Calculate the yearly syringe requirement with wastage**

\[
\text{Annual number of syringes needed} = \text{number of injections administered per year} \times \text{Wastage factor (1.11)}
\]

**Step 3: Calculate the yearly syringe requirement with buffer stock**

\[
\text{Total syringes needed per year} = \text{Annual number of syringes needed} \times \text{buffer stock factor (1.25)}
\]

To combine these 3 steps in one formula:

\[
\text{Total syringes needed per year} = \text{Target Infants} \times 4 \times 1.11 \times 1.25
\]

**Case Study 2**

With the introduction of hepatitis B vaccine into the immunization programme, Dr Taiyyar Kumar is now calculating his additional syringe requirements for the target infants of 60,000. He calculates syringe requirements thus:

\[
\text{Total syringes needed per year} = 60,000 \times 4 \times 1.11 \times 1.25
\]

\[
= 333,000 \text{ syringes}
\]
4. Estimate Storage Needs

Adding hepatitis B vaccine to the UIP requires a re-evaluation of storage capacity at all levels of the programme. Since both exposure to heat and freezing destroys the potency of hepatitis B vaccine, it should be stored at temperatures between +2° C and +8° C only. Hence, assess cold chain requirements at all levels and implement plans, to accordingly revise cold chain storage capacity.

Assessing cold chain storage capacity

Inclusion of hepatitis B Vaccine (as a 10 dose vial) into UIP requires additional storage space. Hence, one needs to estimate the total requirement of cold chain space based on the additional hepatitis B vaccine requirement at each level of storage. The table below outlines the storage capacity of various cold chain equipments.

<table>
<thead>
<tr>
<th>Equipment</th>
<th>Storage Capacity (mixed antigen)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ILR 300 ltrs</td>
<td>60,000 doses</td>
</tr>
<tr>
<td>ILR 140 ltrs</td>
<td>25,000 doses</td>
</tr>
<tr>
<td>Cold Box 20 ltr</td>
<td>6000 doses and 52 Ice Packs</td>
</tr>
<tr>
<td>Cold Box 5 ltr</td>
<td>1500 doses and 20 Ice Packs</td>
</tr>
<tr>
<td>Vaccine Carrier</td>
<td>15-20 vials and 4 Ice Packs</td>
</tr>
</tbody>
</table>
**State and district cold stores** indent vaccines on a quarterly basis. Thus, at the beginning of each quarter, the state/district should have:

- a vaccine stock for 3 months
- additional 25% as buffer stock (1/4 of the estimated annual requirement).

**PHC cold stores**, however, indent vaccines every month. Thus, at the beginning of each month, the PHC should have:

- a vaccine stock of 1 month
- additional 25% as buffer stock (1/12th of the

---

**Case Study 3**

Our friend, Dr Taiyyar Kumar now needs to calculate the new total storage space required with the inclusion of the hepatitis B vaccine. Based on his target infants of 60,000, his annual requirement (including wastage and buffer stock) for already existing antigens* is 1496250 doses. As we had already calculated in Case Study 1, introducing hepatitis B vaccine into the programme would involve an additional 399000 doses. **His total annual requirement is:**

1496250 + 399000 = 1895250 doses

And his **quarterly requirement is:**

1895250/ 4 = 473813 doses.

Since each 300 liter ILR at the district stores 60,000 doses, he calculates his **cold chain requirements** thus:

473813/ 60,000 = 8 ILRs

*1 BCG, 5 DPT, 4 OPV, 1 Measles, 2 TT-PW, 2 TT-10,16
5. Manage Cold Chain

Effects of heating and freezing on vaccine potency

Hepatitis B Vaccine is sensitive to both high temperature and also freezing. The vaccine is stored at +2° C to +8° C. Repeated exposure to temperatures higher than 8° deg C might make the vaccine unusable due to heat damage, which is indicated by VVM on the label.

But more frequently hepatitis B vaccine loses potency upon freezing. Hence protection from temperatures less than +2° C is crucial at all levels of the cold chain. Vaccine freezing does occur at all levels of the cold chain and there is very little awareness of this problem among programme managers. Vaccines that contain adjuvants (such as aluminium salts) are sensitive to freezing. Adjuvants are included in some vaccines to enhance the immunogenicity of the vaccine antigens. These vaccines include hepatitis B, DPT, TT, and DT. In the hepatitis B vaccine, freezing breaks the bond between hepatitis B surface antigen (HBsAg) and the alum adjuvant. Hepatitis B vaccine thus loses its immunological potency when it is frozen.

Preventing vaccine freezing during storage

Vaccine freezing is commonly found to occur at two levels, during storage in ILRs and during vaccine transport to the session sites.

Ways to reduce freezing during storage include:
**In cold rooms**
- store freeze-sensitive vaccines away from evaporator.

**In ice-lined refrigerators (ILRs)**
- keep all vaccines, particularly freeze-sensitive vaccines such as hepatitis B and 'T' series vaccines in the baskets in the ILRs,
- set the thermostat to ensure a temperature of +2° C to +8° C.
- do not adjust the thermostat after power cuts or if the temperature occasionally rises above +8° C.
- ALWAYS ensure sufficient gaps for air circulation while storing the vaccine containing boxes
Job-aid 1: Sticker for Ice Lined Refrigerators
Prevent vaccine freezing during transport

Studies show that the maximum instances of vaccine freezing occur during transport of vaccine to the session sites. To prevent this, follow the steps given below for preparing and conditioning ice packs. (This job-aid can be used as a sticker for vaccine carriers)

Job-aid 2: Sticker for Vaccine Carriers
## Check for heat damage

**Vaccine Vial Monitor (VVM):** A VVM is a label that changes colour when the vial has been exposed to heat over a period of time. Before opening a vial, check the status of the VVM, printed on the vial label or cap. The VVM is a square inside a circle. As the vial is exposed to heat, the square becomes darker. Use only vials with inner squares that are lighter than the outside circle.

<table>
<thead>
<tr>
<th>Scenario</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inner square is lighter than outer circle.</td>
<td><strong>Usable</strong></td>
</tr>
<tr>
<td><em>If the expiry date has not been passed, USE the vaccine.</em></td>
<td></td>
</tr>
<tr>
<td>At a later time, inner square is lighter than outer circle.</td>
<td><strong>Usable</strong></td>
</tr>
<tr>
<td><em>If the expiry date has not been passed, USE the vaccine.</em></td>
<td></td>
</tr>
<tr>
<td>Discard point: Inner square matches colour of outer circle.</td>
<td><strong>Not usable</strong></td>
</tr>
<tr>
<td><em>DO NOT use the vaccine.</em></td>
<td></td>
</tr>
<tr>
<td><em>Inform your supervisor.</em></td>
<td></td>
</tr>
<tr>
<td>Beyond the discard point: Inner square darker than outer circle.</td>
<td><strong>Not usable</strong></td>
</tr>
<tr>
<td><em>DO NOT use the vaccine.</em></td>
<td></td>
</tr>
<tr>
<td><em>Inform your supervisor.</em></td>
<td></td>
</tr>
</tbody>
</table>

**VVM merely indicates the exposure of Hepatitis B vaccine to heat.**  
*Remember that the vaccine is vulnerable to freezing too*
Check for cold damage (freezing)

**Shake test:** The Shake test determines whether adsorbed vaccines (DPT, DT, TT or HepB) have been frozen at some point in the cold chain. After freezing, the vaccine is no longer a uniform cloudy liquid, but tends to form flakes which gradually settle to the bottom after the vial has been shaken. Sedimentation occurs faster in a vaccine vial which has been frozen than in a vaccine vial from the same batch which has never been frozen. **Conduct the test at the storage point when you suspect that a large number of vials have been frozen.** If there is obvious flocculation or freezing, then discard the vials.

**Conducting the Shake Test**

**Step 1** - prepare a frozen control sample: Take a vial of vaccine of the same type, batch and manufacturer as the vial you want to test. Freeze the vial until the contents are solid (at least 10 hours at -10°C) and then let it thaw. This vial is the **control sample**. Mark the vial clearly so that it is easily identifiable and will not be used by mistake.
**Step 2** - choose a **test sample**: Take a vial(s) of vaccine from the batch(es) that you suspect has been frozen. This is the test sample.

**Step 3** - Shake the control and test samples: Hold the control sample and the test sample together in one hand and shake vigorously for 10-15 seconds.

**Step 4** - Allow to rest: Leave both vials to rest by placing the vials on a table and not moving them further.

**Step 5** - Compare the vials: View both vials against the light to compare the sedimentation rate. If the test sample shows a much slower sedimentation rate than the control sample, the test sample has most probably not been frozen and can be used. If the sedimentation rate is similar or more than the control, the test vial has probably been damaged by freezing. It should not be used.
6. Minimize Vaccine Wastage

It is important to minimize the wastage of hepatitis B vaccine just as it is important to minimize the wastage of other vaccines too. It must be remembered that all vaccines cost a considerable amount of money.

Strategies to decrease vaccine wastage include:

- Predicting accurate vaccine requirement based on micro-planning and procuring only required quantities
- Ensure stock position is intimated to higher authorities on a regular basis
- Maintenance of the cold chain at all levels including transport
- Prevention from freezing
- Meticulous planning and conduct of sessions
- Raising demand for immunization services by communication with the community
- Use of vaccine vial monitors (VVM)
- Quarterly monitoring of wastage
**7. Update Recording and Reporting Systems**

Adding a new vaccine requires updating the forms and IEC materials that list the vaccines in the immunization programme.

**Update Forms**

Identify and update all recording and reporting formats to reflect the addition of the new vaccine.

- Vaccine stock forms and
- Immunization cards, UIP reporting formats (Tally Sheets, Monthly Progress Report at all levels (*See Annexure 6, 7 and 8*)
- MCH/Immunization Register
- Monitoring Chart
- Supervisory checklists (*See Annexure 9*)
- Computer databases
- Immunization coverage surveys and evaluations;

It is preferable to revise these formats to include hepatitis B vaccine and distribute them before introduction. Alternatively, existing forms can be adapted locally (e.g. health workers may add hepatitis B vaccine data by hand to existing forms and use these as long as they last). However, errors and omissions are more likely to occur if the latter course is chosen.
Update Informational Materials

Revise and distribute informational materials for the community and caregivers, before the vaccine is introduced. Materials that must be revised include:

- posted immunization schedules, (tin-plates, posters, wall paintings and billboards)
- immunization cards and counterfoils
- materials for parents
- training material for health workers
8. Prepare and Train Staff

Training for health care staff is essential to the introduction of hepatitis B vaccine into the UIP. Health care providers are responsible for handling and administering the vaccine and they are a major source of information for parents and other members of the public. Additional training can be minimized if the delivery of information on hepatitis B disease and vaccine is integrated into existing training programmes. Health care personnel who need training include District Immunization Officers (DIO), Medical Officers (MO), cold chain handlers, supervisors, data managers and frontline Health Workers (HW).

Training Approach

Training activities would commence at the national-level, with an orientation of state officers on hepatitis B vaccine introduction. This would be followed by training of district-level trainers at the State level. In turn, this should be followed by the training of Medical Officers, supervisors and cold chain handlers. Finally, MOs should conduct sensitization of the frontline Health Workers.

Conduct orientation training before the new vaccine is introduced and before public information campaigns are undertaken. Ensure to update all training materials related to immunization to include information about hepatitis B disease and vaccine. Also, advocate for inclusion of information about hepatitis B disease and vaccine in the curricula for health care staff training programmes and medical/nursing courses.
Training Tips

Choosing which training method to use is as important as deciding what to teach. Some points to consider when planning training are:

- Use skill-based training, interactive discussions and hands on approach to teach tasks and procedures.
- Teach in settings that are as close as possible to real work conditions (staff meetings, in-service training workshops and newsletters.)
- Teams that work together should be trained together.
- Ensure follow-up and supervision after training.
- Use every opportunity to reach health care staff, even if this means that some individuals may receive the same information more than once.

Training Content - Broad areas

Training must cover information on hepatitis B vaccine and HBV-related diseases as well as programmatic issues. The main hepatitis B specific topics that should be covered in the training are:

- Types of Hepatitis
- Hepatitis B virus, transmission and disease,
- Importance of infant vaccination
- Hepatitis B vaccine and schedule
- Vaccine and logistics management
- Vaccine administration
- Injection safety, and waste disposal,
- AEFI
- Reports and records
- Communicating with parents.

**Development of Content**

Content should be such that it keeps the interest of the trainees through the length of the training. It should focus on practical aspects which the trainee will be able to put to use immediately after return rather than teach mere theory part of it. Hence for each training session the trainer should develop and modify content in such a way that it foresees and addresses the issues which are relevant to the particular batch of trainees. The material and content in this Operational Guide can be used to prepare the training material. Besides this the two key resources to develop training content are:

- Immunization Handbook for Health Workers
- Immunization Handbook for Medical Officers
Suggested Agenda for training
Of Medical Officers

- Registration (20 min)
- Review objectives/expectations (10 min)
- Pre-test and Warm up (15 min)
- Routine Immunization recap and Introduction to New Vaccines (30 min)
- Hepatitis B Disease and Vaccine, schedule, route of administration, storage and care of vaccine (60 min)
- Inclusion of hepatitis B Vaccine under UIP - Steps in introduction - planning vaccine requirements, assessing cold chain space, session planning (90 min Group exercises)
- Conduct of Immunization session with hepatitis B vaccine - packing the VC, injection technique and safety, recording reporting, (60 Min Demonstration)
- AEFI management and reporting (30 min)
- Increasing Demand for Immunization (30 min) (presentation and role play on IPC)
- Tips for HW training and development of training plan (30 min Micro teaching, Discussion)
- Discussion on Frequently Asked Questions (20 Min)
- Evaluation and Post test (15 min)
Suggested Agenda for half-day Training of Health Workers

- Registration (10 min)
- Pre-test (see Annex 5A) (10 min)
- Review objectives/expectations (10 min)
- Routine immunization recap and discussion on schedules (30 min)
- Hepatitis B Disease and importance of infant immunization (30 min)
- Hepatitis B vaccine and its schedule (10 min)
- Cold Chain maintenance, conditioning of icepacks and packing of vaccine carrier (20 min)
- Injection Technique and Waste management (20 min) (demonstration)
- AEFI (20 min)
- Recording and Reporting (30 min)
- Increasing Demand for Immunization (20 min)

Some of the materials that could be used and disseminated during training sessions are:

- Job aids on vaccine freezing (stickers for ILRs and vaccine carriers)
- CDs with presentation for training (Supplied separately. State and District Trainers to use it)
- Flipbooks for training by MOs (Supplied separately. District and Block trainers to use it)
When including hepatitis B vaccine in the UIP, advocacy and social mobilization are important in order:

- to generate support and commitment for the new vaccine; and
- to dispel misconceptions about the disease and the vaccine that could undermine public confidence

**Advocacy** with key decision makers/opinion leaders is essential to ensure that the vaccine is offered to all eligible infants in every district. **Social mobilization** is needed to ensure that the general public, including caregivers accept the vaccine. These activities are necessary because hepatitis B disease has:

- no external manifestation for most infections;
- an insidious onset and a very long interval before onset of complications;
- an impression of NOT being responsible for these complications; and
- no directly recognizable deaths in most cases

**Advocacy**

Advocacy is a process for raising awareness, especially among decision-makers and service providers, to ensure that the service (hepatitis B immunization) is available for all children. Increasing awareness in the community of the importance of HBV as a cause of disease and death is a key activity and requires sound scientific data on the current and
future disease burden. Another critical aspect is to show the impact of immunization in preventing that disease burden. As nearly all disease prevention will occur several decades after delivery of immunization in that cohort, special advocacy efforts are needed.

The **decision-makers and opinion leaders** who should be considered in this connection include:

- health department officials
- other government officials
- elected representatives at state, district and panchayat levels
- clinicians in the private sector
- nongovernmental organizations
- community leaders and decision-makers
- media
- religious leaders, and
- teachers

The **key messages** for these groups could include:

- the disease burden associated with HBV-related cirrhosis and liver cancer in India or in the state;
- modes of HBV transmission;
- importance of infant immunization in preventing chronic hepatitis B;
- the efficacy and cost-effectiveness of hepatitis B immunization;
- the safety of hepatitis B vaccine;
Possible key messages for policy-makers

• Infant immunization for hepatitis B will prevent large number of chronic liver diseases decades later.

• Of the 2.6 crore infants born every year in the country, around 10 lakh run the life-time risk of developing chronic HBV infection of whom 1-2 lakh may suffer serious liver disease including cancer.

• Infant Immunization is highly cost effective in preventing liver cirrhosis and cancer.

• There is no cure for hepatitis B. Prevention is better!

• Sustained high coverage with hepatitis B vaccine can virtually eliminate hepatitis B infections in 10-15 years.
Launching of Hepatitis B vaccination

Introduce the vaccine into the programme with a well publicised launch. Utilize the opportunity to educate the public and the policy makers alike about the disease, its prevention and how the immunization benefits the individual and the nation. For a successful launch apart from the mass media event one to one contact with people (Interpersonal Communication-IPC) is equally important. In this, take the help of other government departments, local media and NGOs that can spread the message and motivate the community to utilize immunization.

Social Mobilization

Social mobilization is similar to advocacy, but has different target audiences (caregivers) and is focused on getting children to the immunization session. A range of media should be used to deliver the messages, including health workers, aanganwadi workers (AWWs), Accredited Social Health Activists (ASHA), community volunteers and the mass media. Health workers, in particular, can be motivated to generate interest in the new vaccine as this can improve coverage of other vaccines. They are the main source of information to the general public.

Possible key messages for the parents and general public are:

- Hepatitis B and its consequences
- modes of HBV transmission
- importance of infant immunization
- the target group for immunization, and an explanation of why older children are not being immunized with hepatitis B vaccine
- how many times and when infants should be immunized - make sure that the baby is immunized at birth at the hospital and later three times with DPT and OPV at 6, 10 and 14 weeks age
- Importance of all other vaccines of UIP in addition to hepatitis B vaccine
- limitations of hepatitis B vaccine

Social Mobilization Channels

Surveys show that the best channels for increasing demand for immunization are health workers, AWWs, local leaders and local groups. Generally, parents perceive health workers as a credible source of information about health. Inter-personal communication is the best way to give parents information about the hepatitis B vaccine and when and where to bring their child for the vaccination.

Mass communication media, involving radio, TV and print materials, can complement the basic channel of IPC, but it is not a substitute for it and is inadequate by itself.

Prepare to respond in a timely manner to misconceptions about hepatitis B disease and vaccine that could undermine public confidence in the programme. Misconceptions about the safety of hepatitis B vaccine may also occur because of case reports of AEFI's.
### Activities/ Materials for Introducing Hepatitis B Vaccine

<table>
<thead>
<tr>
<th>Materials</th>
<th>Intended Use</th>
<th>Main Messages</th>
</tr>
</thead>
</table>
| IPC (ANM, AWW, ASHA, etc.)        | To initiate discussions with small groups of parents as part of RI sessions and on other occasions | • Basic facts about hepatitis B disease and vaccine  
• When and where to bring children for immunization  
• Bring RI card for every visit.  
• Treating side effects |
| Info-kit for health workers (Annexure 1 and Annexure 2) | A reference for health workers helping them respond to parents’ questions and listing their duties | • Basic facts about hepatitis B disease and vaccine  
• What health workers have to do to while adding hepatitis B vaccine |
| Pamphlet for community leaders (Annexure 4) | A reference for community leaders to help plan support activities and respond to public’s questions | • Basic facts about hepatitis B disease and vaccine  
• What leaders can do to provide support |
| Pamphlet for parents (Annexure 3) | A reference for parents to clarify doubts regarding the vaccine and the schedule | • Basic facts about hepatitis B disease and vaccine  
• Ages at which children should get vaccines  
• Importance of immunization |
| Posters, hoardings, banners, wall painting | To raise public awareness and provide information about the immunization schedule | • Vaccines in the UIP, including hepatitis B  
• Ages at which children should get vaccines  
• Importance of immunization |
| Print, Radio and television spots | To raise awareness among the public, community leaders, and health workers | • Increased protection to the public through hepatitis B vaccine  
• No additional visits needed for getting the vaccine  
• Caregivers should bring children for all vaccines |
Dissemination Strategy

Ensure timely dissemination of guidelines, tools, and other communication materials to the appropriate audiences. Failures in communication commonly occur because the disseminated materials sometimes do not reach and or the formats are not appropriate for the intended audience. The materials often end up at warehouses at some intermediate point. A few general guidelines for more effective dissemination are the following:

Design a dissemination plan that specifies:

- who is supposed to use and therefore receive the materials
- in what quantity end-users need them
- by what means they will be sent to the intended users
- who is responsible for sending them
- the budget needed to do so.

Additionally,

- Use those channels that are most convenient for the audience, not those most easy for the programme managers (e.g. mass media).
- Ask audience members what channels and formats are easiest for them to use.
- Monitor dissemination - that the material is reaching the intended people and that they feel it is appropriate and useful for them.
10. Supervise, Monitor and Evaluate

Supervise planning and implementation

Supervision in the planning phase is focused on checking the infrastructure and human resource capacity and to solve them, and after inclusion of hepatitis B vaccine in the schedule, it is focused on checking the adequacy of implementation and on preventing deviations from guidelines. Supervision must focus on the critical aspects of quality, effectiveness and safety and on anticipated weaknesses. Supervisors have an important role to prevent bad plans and to alter poor implementation. To achieve this, Supervisors must themselves be familiar with what is expected in the programme and what role they are expected to play. A key component of supervision is to encourage and motivate frontline health workers (ANMs, AWWs, ASHAs) and guide them through on the job training, wherever necessary.

Tools for supervision

Supervisors should use a checklist (Annexure 9) as a tool to document the level of implementation of plans, and coverage with the vaccine. The checklists to be used by your state should be developed locally if local specific additional information is required and if the form is required in local language.
**Schedule supervisory visits**

Supervising officers should visit some of the immunization sessions in action to observe the actual implementation of the programme in the field. During the visit they should try to assess the proper maintenance of the cold chain, safe disposal of AD syringes and actual coverage of beneficiaries with all the doses of vaccines under UIP by sample checks in the field and find out any weaknesses, or constraints. Supervision should be conducted as per a pre determined plan at various levels as below:

**At the state level:** Supervisors from the state level should make supervisory visits to all districts before the introduction of the vaccine. If that is not possible, visit selected districts and blocks, with particular difficulties or questionable preparations for logistics or social mobilization.

**At the district level:** Supervisors from the district should make planned supervisory visits to all blocks/PHCs, particularly with difficulties or questionable preparations for logistics or social mobilization.

**At the block/PHC level:** Supervisors from the block/PHC should make supervisory visits to selected immunization session sites.

**At all levels:** In addition to the above, supervisory visits may be needed at all levels, depending on the outcome of the scheduled visits.
Monitor implementation

Incorporate the monitoring of hepatitis B vaccine introduction into routine monitoring systems as soon as the vaccine is included in the UIP. Staff at all levels should closely monitor progress in vaccine introduction, particularly during the first year.

With the addition of hepatitis B vaccine to the UIP, a fully immunized (FI) child is defined as the one completing HepB3 in addition to other traditional vaccines in the UIP schedule by one year of age.

Develop a monitoring plan which could include monitoring of:

- Vaccine and Logistic Supply
- Vaccine Utilization and Wastage
- Cold Chain
- Injection Safety and waste disposal
- Vaccination Practice at Immunization sites
- Implementation of training, IEC and social mobilization.

Monitor vaccines and logistics supply

Examine available records for supply, utilization and balance of vaccines and AD syringes and physically verify whether there is a logical association between the vaccines and AD syringes supplied and used. Explore and address reasons if the following are found:
- the utilization of the vaccine and AD syringes shows a pattern of rapid increase or decrease week after week; or
- the doses consumed for vaccines to be provided at the same time (DPT, HepB and OPV) differ widely from each other for the same period.

If there is any mismatch between the reported number of doses and AD syringes used, consult the concerned vaccinators, doctors, store in charge and supervising authorities to find out the reason for the variance/mismatch. If their reply is found convincing and realistic appreciate and thank them. If the reply points towards problems or irregularity in work/management, discuss solutions with the concerned persons and also inform the senior authorities.

**Monitor vaccine utilization (coverage)**

Hepatitis B vaccine coverage can be monitored using both reported and evaluated coverage data.

**Use reported coverage data**

In general, coverage data of UIP, is reported by all levels. Analyze HepB3 and DPT3 immunization coverage data at every level on at least a quarterly basis. This will help in planning, to correct problems and to monitor programme impact. Using reported data to estimate coverage has its advantages. The information is timely, the method makes use of numbers that are already routinely gathered and the data can point out problems in service delivery.
However, coverage estimates based on such data may be biased when the size of the target population is wrong or, more commonly, when reports on the number of doses administered are incomplete. This can lead to overestimation or underestimation of coverage. To ensure completeness and accuracy, state and district immunization managers should audit reported data from districts and blocks periodically, preferably on a quarterly basis, particularly, in the first year after inclusion of hepatitis B vaccine. The following are examples of reported data that can be used to monitor hepatitis B immunization.

**HepB3 Coverage:** This measures the proportion of infants who complete the hepatitis B immunization series.

\[
\frac{\text{Children immunized with HepB3 by 1 yr of age}}{\text{Target population (children under 1 yr of age)}} \times 100
\]

**HepB1 vs. HepB3:** This monitors the drop-out rate (the proportion of children that are incompletely vaccinated) for HepB

\[
\frac{(\text{HepB1} - \text{HepB3})}{\text{HepB1}} \times 100
\]

The dropout rates for hepatitis B vaccine should not be higher than drop-out rates for DPT and OPV. Use the WHO vaccine coverage monitoring chart to monitor these indicators graphically and provide feedback to lower administrative levels.
**HepB3 vs. DPT3:** This monitors completion of the hepatitis B vaccine series in comparison with that of the DPT series. By the time the child has completed the DPT series it should have received the last (third or fourth) dose of hepatitis B vaccine.

\[
\frac{(\text{DPT3} - \text{HepB3})}{\text{HepB3}} \times 100
\]

If DPT3 coverage exceeds HepB3 coverage by more than 5%, assess missed opportunities for administering hepatitis B vaccine, which may include:

- Concern about wasting expensive vaccine leading to:
  - Reluctance to open a vial for one child.
  - HepB vaccine offered less often than DPT vaccine.
  - HepB vaccine not available at all session sites.

Other reasons for missed immunization:
- Hepatitis B vaccine shortages or supply problems.
- False belief that hepatitis B vaccine has excessive contraindications.
- Inadequate staff training to administer new vaccine.
- In the case of monovalent vaccine, reluctance of mothers to accept multiple injections.

**HepB-birth coverage:** Measuring the percentage of children receiving hepatitis B vaccine within 24 hrs after birth provides an indicator of the success of the programme in preventing perinatal HBV infections.

**Use evaluated coverage data**

Immunization coverage surveys are useful for obtaining additional information relating to any improvement in immunization coverage. They often provide more accurate information than reported data. Standard questionnaires used for EPI surveys have to be modified to include hepatitis B vaccine doses. The important surveys of UIP coverage are:

- UNICEF Coverage Evaluation Survey
- National Family Health Survey (NFHS); and
- District Level Household Surveys (DLHS)

Serological surveys can also be used to provide serologic evidence of receipt of vaccination.

**Monitor immunization safety**

Although, hepatitis B vaccine is very safe, all AEFIs suspected by health workers or the public to be associated with hepatitis B vaccination should be reported in the prescribed GoI formats, including absceses, hospitalizations, deaths and
any other severe or unusual medical event or event clusters. Check compliance with safety strategies from existing supervisor checklists (Annexure 9) and seek explanations for deviations from safety norms, such as recapping, non-use of hub-cutters and other incorrect practices.

**Monitor cold chain**

The consequences of failures in the cold chain are well known - hepatitis B vaccine gets damaged by higher temperatures as well as by freezing. The system will end up delivering vaccines that are no longer potent and effective if proper cold chain is not maintained. Therefore strict attention to maintenance of cold chain is essential. The basic information that should be known to a supervisor/programme manager on the cold chain and the capacity and maintenance of various equipments is summarized earlier.

**Evaluate impact**

The ultimate outcomes of hepatitis B immunization (preventing chronic HBV infection and its long-term consequences - cirrhosis and liver cancer) are difficult to measure. However, serological surveys can provide data on reduction in rates of HBV infection, compared to baseline HBsAg positivity data already available. Thus, a serological survey of 3-5 year old children conducted approximately 5 years after the full implementation of the hepatitis B
immunization programme and comparison with results from children of similar age in previous surveys can also provide data on programme's effectiveness, as part of a long-term evaluation process.
ANNEXURES
Annexure1: Information for Health Workers:
20 Frequently Asked Questions about
Hepatitis B Disease and Vaccine

1. What is hepatitis B?
Hepatitis B is a type of disease due to infection and inflammation (swelling) of liver caused by hepatitis B Virus (HBV). Infection with HBV can cause short term (acute) or long-term (chronic) disease.

2. What are the clinical features of acute and chronic hepatitis B?
About 10% of infants and up-to 30% adults infected by HBV develop a short-term (acute) illness with the following clinical features:
- Fever (mild or absent)
- Loss of appetite
- Tiredness
- Pain in muscles, joints
- Nausea, diarrhoea and vomiting
- Pain abdomen
- Headache
- Dark urine
- Pale stools
- Jaundice

The incubation period is usually 2 to 5 months. Although most acute infections resolve normally, a few (about 1% of acute infections) can lead to fulminant hepatitis and can result in death.

In contrast, 90% of infants, 30% of children of 1-5 yr and about 6% adults infected with HBV develop chronic infections. Chronic infections remain sub-clinical for a long time without symptoms. Persons with chronic infection have a 15-25% risk of dying prematurely due to HBV related liver cirrhosis and cancer. Most of the chronic carriers of HBV look healthy but are capable of spreading the disease to others.
3. Why is hepatitis B a public health problem?

HBV infection is a major cause of acute and chronic liver disease. About one-third of the world’s population i.e. about 200 crore (two billion) persons, are estimated to be infected with HBV. Of these 35 crore (350 million) suffer from chronic infection. The majority of the long term serious consequences of infection with HBV such as liver cirrhosis and cancer occur in people who develop the chronic infection. Worldwide about 5,00,000 - 7,00,000 die annually from hepatitis B related complications.

4. Who is at risk of getting hepatitis B?

Anyone who has not been vaccinated can get HBV. Infants and children are particularly vulnerable for chronic infections. Children contract the disease from their mother at birth, or simply from another child while playing. Chronic infections from infancy are dangerous because of the liver damage and cancer.

5. How is hepatitis B spread?

HBV is transmitted through contact with infected blood or body fluids across skin/mucous membrane and unprotected sexual intercourse. HBV is 100 times more infectious than Human Immunodeficiency Virus (HIV). Unlike HIV, HBV is able to remain active on surfaces (e.g. table tops, razor blades, blood stains etc) for about a week.

The primary ways HBV can be spread are described below.

Child-to-child transmission: This (including adult to child) is one of the common modes of transmission. Infants and children frequently have no symptoms following hepatitis B infection. The infected child may look perfectly healthy. Child-to-child transmission usually
happens during play, mock fights, scratching, biting etc. as a result of contact through skin sores, small breaks in the skin, or mucous membranes with blood, sores or saliva. Spread from inanimate objects, such as sharing of toys towels or toothbrushes may also occur because HBV can survive for at least 7 days outside the body.

**Mother to baby (peri-natal) transmission:** Transmission from an infected mother to her baby usually happens at the time the baby is born.

**Unsafe injections and blood transfusion:** Unsafe injection practices such as sharing of needles by drug users, transfusion of untested blood or other unsafe medical procedures are a major source of HBV transmission

**Sexual transmission:** HBV spreads through unprotected sexual intercourse. It is 100 times more infectious than HIV.

6. **How big a health problem is hepatitis B in India?**

Hepatitis B is a major health problem in India. India falls under intermediate prevalence rate of HBV, with about 4 crore (40 million) HBsAg carriers in India. Of the 2 crore 60 lakhs (26 million) infants born every year in India, around 10 Lakh (1 million) run the life-time risk of developing chronic hepatitis B infection.

7. **Are there any other types of hepatitis virus?**

Yes, in addition to Hepatitis B, there are Hepatitis A, Hepatitis C, Hepatitis D and Hepatitis E viruses. However hepatitis B is the most common cause of serious illness and death among all the types of hepatitis.

8. **Is there a cure against hepatitis B?**

There is no known cure for hepatitis B; this is why prevention with hepatitis B vaccine is so important.

9. **How can hepatitis B be prevented?**

Hepatitis B can be prevented by a full series of hepatitis B
vaccination. Hepatitis B vaccine is effective in preventing HBV infections if given either before or shortly after exposure (within 7 days). The vaccine has a high protective efficacy rate, particularly in children.

10. How effective is the vaccine?
The complete vaccine series of hepatitis B vaccine induces protective antibody levels in more than 95% children.

11. What are the limitations of hepatitis B vaccine?
HBV is one of five viruses known to cause hepatitis in humans. Hepatitis B vaccine only protects against hepatitis B and not other diseases that cause jaundice.

12. How safe is the hepatitis B vaccine? What are its side-effects?
Hepatitis B vaccine is a very safe vaccine with proven efficacy. Since 1982, over 100 crore (1 billion) doses of hepatitis B vaccine have been used worldwide.

Mild transient side effects:
Most common side effect is pain at the injection site. Mild systemic complaints like fatigue, headache, irritability and fever higher than 37.7°C which may usually start within a day after the vaccination and may last for one to two days.

Serious allergic (anaphylactic) reactions:
Serious allergic reactions to the vaccine are rare at about 1-2 per 10 lakh (1 million) doses and may include: generalized urticaria, difficulty in breathing, swelling of the mouth and throat, hypotension, shock

13. Who should get the hepatitis B vaccine?
All infants should receive hepatitis B vaccine.

14. How many doses are needed? When should they be given?
A Birth dose and irrespective of the birth dose three further doses should be given to all infants. Birth dose is to be given as early as
possible after birth preferably within 24 hours for all institutional deliveries. Irrespective of the Birth dose, all children receive 3 doses at 6, 10 and 14 weeks age given at the same time as DPT although at different sites.

15. Are there any contraindications to the hepatitis B vaccine?
The only two absolute contraindications to withhold or postpone the administration of the hepatitis B vaccine are:

- A severe allergic reaction to a vaccine component or following a prior dose of hepatitis B vaccine. Such allergic reactions are rare. Further doses are contraindicated if there is a history of anaphylaxis to a previous dose.

- Persons with moderate or severe acute illness should not be vaccinated until their condition improves. However, a minor illness, such as an upper respiratory infection, is not a contraindication to vaccination.

16. How is the vaccine presented?
It is a cloudy liquid that comes in a ten-dose vial and does not require reconstitution. If the vaccine is allowed to stand for a long time, it separates from the liquid and looks like fine sand at the bottom of the vial. The vaccine must be mixed by shaking.

17. How is the vaccine stored?
The storage temperature for hepatitis B vaccine is the same as for all other T series (DPT, DT, TT) vaccines in the UIP, between 2°C and 8°C. Hepatitis B vaccine should never be frozen. Freezing the vaccine causes it to lose its potency.

18. What are the safety measures to be followed at the time of vaccine administration?
Ensure that the following safety measures at the time of vaccine administration:

- Check the expiry date
- Check VVM to ensure that the vaccine is usable
- Do not use any frozen vaccine.
- Do not use any vial without label
- Do not try to mix more than one vaccine into the same syringe
- Use only AD syringes supplied for the purpose
- Follow the waste disposal guidelines

19. What is the dosage and site of administration of the vaccine?

The standard paediatric dose of hepatitis B vaccine is 0.5ml. Hepatitis B vaccine is administered by intra muscular injection in the antero-lateral aspect of the thigh. It should NOT be given in the buttock. It can safely be given at the same time as DPT and OPV vaccines. When hepatitis B vaccine is administered on the same day as DPT, the vaccines should be given in opposite limbs.

20. How will the reports of hepatitis B vaccine be submitted?

Reports will be sent in the UIP format to the PHC from Health worker and from PHC upwards up to National level consolidated on a monthly basis.
Annexure 2: Roles of Health Workers in the Introduction of Hepatitis B Vaccine

The introduction of the hepatitis B vaccine in the UIP is an important advancement for public health in India. You can help by:

1. Informing families about this new vaccine and its benefits.
2. Giving clear answers in simple language in response to questions from the public.
3. Conducting meetings with community leaders to orient them to the introduction of this new vaccine and about how they can better support the immunization programme.
4. Checking the immunization cards of children to see if any of them need vaccines or more doses of vaccines. Administer the vaccines as needed.
5. Treating the mothers or guardians with respect. Remember, in order to protect the health of children, it is essential to have collaboration between health workers and mothers or guardians of the children.
6. Assuring that each mother or guardian of the vaccinated child knows:
   • which vaccines the child received,
   • the possibility of side effects and what to do in the case of these effects
   • when to return for the next dose or vaccination
   • to keep the immunization card safe and bring it along for the next visit
7. Reminding parents about the dates and sites of immunization sessions
8. Following all of the instructions for storage and use of the vaccines.
9. Providing vaccine to all eligible infants following injection safety measures meticulously
10. Provide first aid and report all AEFIs immediately to the MO, and provide referral services in case of any serious AEFI.

11. Team up with AWW and ASHA to ensure the success of the programme.

12. Engage village elders and Panchayat members and obtain community support to the programme.

13. Utilize the opportunity of Village Health Day to provide key messages to the community.
Annexure 3: Information for parents - 10 Frequently Asked Questions about Hepatitis B Disease and Vaccine

1. What is hepatitis B?

Hepatitis B is a serious liver disease caused by the HBV, which occurs in the blood and body fluids of infected individuals. When persons are infected with HBV they may have features of acute infection:

- Fever (mild or absent)
- Loss of appetite
- Tiredness
- Pain in muscles, joints
- Nausea, diarrhoea and vomiting
- Pain abdomen
- Headache
- Dark urine
- Pale stools
- Jaundice

More seriously, HBV infections during infancy and childhood frequently cause chronic (long-term) infection that can stay undetected without any symptoms in the body for decades before it leads to:

- permanent liver damage (cirrhosis);
- liver cancer
- death

2. Who can get hepatitis B? Who is most at risk?

Anyone can get hepatitis B, but infants and young children are most at risk. Although infants and young children rarely become sick on acquiring the infection, they are at high risk of developing chronic infection with HBV. Chronically infected persons are at high risk of dying from cirrhosis and liver cancer.
3. **How is hepatitis B virus spread?**

The main ways in which it spreads are:

a. from mother to baby at birth  
b. from child to child and adult to child  
c. through unsafe injections and transfusions  
d. through unprotected sex with an infected person  

The hepatitis B virus is found in the blood and body fluids of an infected person. It spreads to others when they come into contact with the blood or body fluids of infected person through small breaks in the skin and mucus membrane.

4. **Can hepatitis B be prevented?**

Yes. A safe and effective vaccine has been available since 1982. About 95% of infants who get at least 3 doses of the vaccine will be protected.

5. **Who should get hepatitis B vaccine?**

All infants should get hepatitis B Vaccine.

6. **How many doses are needed? When should they be given?**

Usually, hepatitis B vaccine is given at birth as early as possible after birth preferably within 24 hours and irrespective of the birth dose, three doses are given at 6, 10 and 14 weeks age at the same time as DPT and OPV. It is safe to give hepatitis B vaccine and DPT on the same day at different sites. All doses must be given to ensure that your child is protected. If a dose is missed it should be given as soon as possible. There is no need to start the schedule again.

7. **How is hepatitis B vaccine given?**

Hepatitis B vaccine is given by intramuscular injection in the mid-thigh (front and outer part of mid thigh). It can safely be given at the same time as other vaccines, such as DPT, OPV, Measles and BCG vaccines but at different sites by different syringes and not by mixing them in a common syringe.
8. Does it cost anything to get the hepatitis B vaccine?
No. All vaccines under routine immunization including hepatitis B are given free of cost at all government health facilities.

9. What are the side-effects of hepatitis B vaccine?
Hepatitis B vaccine is very safe. A few infants may suffer side-effects such as redness, swelling and pain at the injection site and mild fever that may last one or two days. Severe allergic reactions are extremely rare.

10. Is there any situation when a child should not be given hepatitis B vaccine?
A child who has had a severe reaction to a previous dose of hepatitis B vaccine should not be given another dose. If a child has a high fever the vaccine may be given at a later visit.

"Hepatitis B vaccine given early in life protects and saves the child from suffering some of the serious liver diseases later in life and also reduces spread of hepatitis B in the community"
Annexure 4: Information for Community Leaders

Government of India is including hepatitis B vaccination for infants in your State under Universal Immunization Programme. The vaccine will be given as an injection along with other vaccines already being given under the programme such as Oral Polio Vaccine (OPV) and DPT. This will help the infants fight one more killer disease hepatitis B, apart from the earlier six diseases being fought through UIP.

This represents an important advance for public health because it will help reduce a major public health burden in India. At present it is estimated that annually, out of the 2 crore 60 Lakh (26 million) infants born every year in the country, around 10 Lakh (1 million) run the life-time risk of developing chronic hepatitis B Virus infection. Of these about 1.5 Lakh are likely to develop serious liver diseases such as cirrhosis, and cancer causing suffering and premature death at their peak productive age (30-50 yr). The vaccine given during infancy, helps prevent the hepatitis B virus infection and associated chronic complications later in life. The success of introduction of this vaccine in your community depends on your collaboration.

How can you help your community receive the hepatitis B vaccine?

- Inform families about the inclusion of hepatitis B vaccine in the routine immunization. All vaccines under routine immunization are provided free of cost.
- Explain to families the benefits of the vaccine which are: more protection without additional effort
- Be sure that each family knows that their child needs to get all the doses of vaccine as per the schedule (At birth for all institutional deliveries and later at 6, 10 and 14 weeks age along with 3 doses of DPT Injection and Oral Polio drops)
- Motivate families to complete vaccination of the child during its first year of life.
- Remind mothers to check immunization cards for the date of the next vaccination.

By Supporting the Immunization Programme, you are taking care of the health of your community. Congratulations!
Annexure 5A: Health Worker Training Pre-Test

1. Please fill in the blank cells in the Infant Immunization Schedule

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Disease(s) prevented</th>
<th>Number of Dose(s)</th>
<th>Route</th>
<th>Site</th>
<th>Vaccine damaged by freezing</th>
</tr>
</thead>
<tbody>
<tr>
<td>BCG</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DPT</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>OPV</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hep B</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Measles</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

2. By what age should a child be fully immunized?

3. A 2-year-old has a card that shows only these vaccines given: BCG, DPT, OPV and HepB given at age 3 months and DPT, OPV and Hep B at age 6 months. Which vaccines would you recommend for today?

4. Is the hepatitis B vaccine effective against all forms of jaundice?

Score: For questions score 1 point for each correct answer.
Annexure 5B: Health Worker Training Pre-Test Answer key

1. Please fill in the blank cells in the Infant Immunization Schedule

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Disease(s) prevented</th>
<th>Number of Dose(s)</th>
<th>Route</th>
<th>Site</th>
<th>Vaccine damaged by freezing</th>
</tr>
</thead>
<tbody>
<tr>
<td>BCG</td>
<td>(TB)</td>
<td>(1)</td>
<td>(ID)</td>
<td>(Lt upper arm)</td>
<td>No</td>
</tr>
<tr>
<td>DPT</td>
<td>(Diphtheria Pertussis Tetanus)</td>
<td>(3)</td>
<td>(IM)</td>
<td>Antero Lateral aspect of mid-Thigh</td>
<td>Yes</td>
</tr>
<tr>
<td>OPV</td>
<td>(Polio)</td>
<td>(4)</td>
<td>Oral</td>
<td>(Mouth)</td>
<td>No</td>
</tr>
<tr>
<td>Hep B</td>
<td>(Hep B)</td>
<td>(4)</td>
<td>(IM)</td>
<td>(Antero Lateral aspect of mid-Thigh) not on the same thigh as DPT</td>
<td>Yes</td>
</tr>
<tr>
<td>Measles</td>
<td>(Measles)</td>
<td>(1)</td>
<td>(SC)</td>
<td>(Right upper arm)</td>
<td>No</td>
</tr>
</tbody>
</table>

2. By what age should a child be fully immunized? (Ans: 1 year)

3. A 2-year-old has a card that shows only these vaccines given: BCG, DPT, OPV and Hep B given at age 3 months and DPT, OPV and Hep B at age 6 months. Which vaccines would you recommend for today? (Ans: DPT and Measles)

4. Is the hepatitis B vaccine effective against all forms of jaundice? (Ans: No)

**Score:** For questions score 1 point for each correct one.
Annexure 6:

**REPORTING FORM OF IMMUNIZATION SESSION SITE (Tally Sheet)**

<table>
<thead>
<tr>
<th>Name of PHC/Sub Centre</th>
<th>Name of village/Mohalla</th>
<th>Date of session:</th>
<th>Place</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Children</th>
<th>Less than 1 year</th>
<th>More than 1 year</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vaccine</td>
<td>Tally Total</td>
<td>Tally Total</td>
</tr>
<tr>
<td></td>
<td>Male Female</td>
<td>Male Female</td>
</tr>
<tr>
<td>BCG</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DPT1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DPT2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DPT3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DPT Booster 1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>OPV 0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>OPV1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>OPV2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>OPV3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>OPV Booster</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Measles</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vit. A1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vit. A2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vit. A3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vit. A4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vit. A5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vit. A6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vit. A7</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vit. A8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vit. A9</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HepB0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HepB1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HepB2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HepB3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DPT Booster 2</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Women</th>
<th>Pregnant women</th>
<th>Others</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tally</td>
<td>Total</td>
<td>Tally</td>
</tr>
<tr>
<td>TT1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TT2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TT Booster</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Issues</th>
<th>Consumed</th>
</tr>
</thead>
<tbody>
<tr>
<td>AD SYRINGES</td>
<td>0.5 ml</td>
</tr>
<tr>
<td>DISPOSABLE SYRINGES</td>
<td>5 ml</td>
</tr>
<tr>
<td>HepB VIALS</td>
<td>1. ANM. :</td>
</tr>
<tr>
<td>BCG VIALS</td>
<td>2. Supervisor :</td>
</tr>
<tr>
<td>DPT VIALS</td>
<td></td>
</tr>
<tr>
<td>OPV VIALS</td>
<td></td>
</tr>
<tr>
<td>MEASLES VIALS</td>
<td>Signature of ANM:</td>
</tr>
<tr>
<td>TT VIALS</td>
<td></td>
</tr>
</tbody>
</table>

Signature of ANM:
Annexure 7:  
UNIVERSAL IMMUNIZATION PROGRAMME  
MONTHLY SUBCENTRE REPORT

<table>
<thead>
<tr>
<th>Subcentre</th>
<th>MONTH</th>
<th>DISTRICT</th>
</tr>
</thead>
</table>

Yearly Target:
- Infants: 
- Pregnant women:

Number of Sessions:
- Planned: 
- Actually held: 

Number of Sessions where vaccines received: 
- Number of Volunteers / ASHA engaged to mobilise children:

Number of sessions held at Aanganwadi centres: 
- Number of fully immunized infants:

<table>
<thead>
<tr>
<th>Number of Sessions for which private vaccinators hired</th>
<th>ANM absent</th>
<th>Underserved areas</th>
<th>Urban slums</th>
<th>Total</th>
</tr>
</thead>
</table>

(A) IMMUNIZATION AND VIT. A.

<table>
<thead>
<tr>
<th>Timings</th>
<th>Pregnant women</th>
<th>Tetanus Toxoid</th>
<th>Doses</th>
<th>For the month</th>
<th>Cumulative</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Vaccines | Doses | For the month | Cumulative |
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Vaccines</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

(B) SURVEILLANCE

<table>
<thead>
<tr>
<th>Disease</th>
<th>For the month</th>
<th>During The year</th>
<th>Cases</th>
<th>Death</th>
<th>Cases</th>
<th>Death</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diphtheria</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pertussis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tetanus Neonatorum</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tetanus others</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acute Flaccid Paralysis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Measles</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Childhood Tuberculosis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

(C) UNTOWARD REACTIONS FOLLOWING IMMUNIZATION

<table>
<thead>
<tr>
<th>UNTOWARD REACTIONS</th>
<th>During the Month</th>
<th>Year</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reported deaths</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of abscess</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other Complications</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
# Annexure 8: Universal Immunization Programme

## Monthly PHC Performance Report

### Yearly Target:
- Infants: [Target]
- Pregnant Women: [Target]

### Number of Sessions:
- Planned: [Number]
- Actually Held: [Number]
- Where vaccines were received: [Number]

### Participation:
- Volunteers/ASHA engaged: [Number]
- Children mobilised: [Number]
- Sessions held at Aanganwadi centre: [Number]

### Immunization and Vitamin A

<table>
<thead>
<tr>
<th>Vaccines</th>
<th>Doses</th>
<th>For the Month</th>
<th>Cumulative</th>
</tr>
</thead>
<tbody>
<tr>
<td>BCG</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>OPV</td>
<td>2</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>DPT</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Hepatitis B (Where introduced)</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>MEASLES</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>VITAMIN A</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>OPV Booster 1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>DPT Booster B1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>VITAMIN A</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
</tbody>
</table>

### Vaccine Supplies (in Doses)

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Opening Balance</th>
<th>Received during the month</th>
<th>Consumed during the month</th>
<th>Unsuitable during the month</th>
<th>Balance at the end of the month</th>
</tr>
</thead>
<tbody>
<tr>
<td>DPT</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>OPV</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BCG</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MEASLES</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TT</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DT</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>VITAMIN A</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HEPATITIS B</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Ad Syringes Supplies

<table>
<thead>
<tr>
<th>AD Syringes</th>
<th>Opening Balance</th>
<th>Received during the month</th>
<th>Consumed during the month</th>
<th>Closing Balance</th>
<th>Disposed as per CPCB norms</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.1 ml</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.5 ml</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5 ml</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Surveillance

<table>
<thead>
<tr>
<th>Disease</th>
<th>Cases</th>
<th>Death</th>
<th>Cases</th>
<th>Death</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diphtheria</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pertussis</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tetanus Neonatorum</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tetanus others</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acute Flaccid Paralysis</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Measles</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Childhood Tuberculosis</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Status of PHC Cold Chain Equipment

<table>
<thead>
<tr>
<th>Equipment make</th>
<th>Machine Number</th>
<th>Whether Working</th>
<th>If not date of breakdown</th>
<th>Date of intimation</th>
<th>Date of Restoration</th>
<th>Remarks</th>
</tr>
</thead>
</table>

### Uptoward Reactions

<table>
<thead>
<tr>
<th>Date</th>
<th>Medical Officer</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>DIO</td>
</tr>
<tr>
<td>2</td>
<td>State EPI Officer</td>
</tr>
<tr>
<td>3</td>
<td>Assistant Commissioner (Immunization, Room No. 106 D, Nirman Bhawan, New Delhi-110001</td>
</tr>
<tr>
<td></td>
<td>email: <a href="mailto:polioindia@yahoo.com">polioindia@yahoo.com</a> ; <a href="mailto:riindia2008@gmail.com">riindia2008@gmail.com</a></td>
</tr>
</tbody>
</table>

### Footnotes
- [A] IMMUNIZATION AND VIT. A.
- [B] VACCINE SUPPLY (IN DOSES)
- [C] AD SYRINGES SUPPLY
- [D] SURVEILLANCE
- [E] STATUS OF PHC COLD CHAIN EQUIPMENT
- [F] UNTOWARD REACTIONS
### Annexure 9: Supervision Checklist at Immunization Session site

<table>
<thead>
<tr>
<th>Sl. No</th>
<th>Date of Visit</th>
<th>Supervisor</th>
<th>PHC</th>
</tr>
</thead>
<tbody>
<tr>
<td>Name of Sub-centre</td>
<td>Location (PHC/SC/AWC/Panchayat/UHC)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Adherence to Micro plan
1. Session held in the village/mohalla specified in micro plan (date AND place) [Yes] [No]

#### Cold Chain and Logistics
2. Collection of vaccines on same day/ vaccine delivered at session site [Yes] [No]
3. Use of vaccine carriers with 4 ice packs [Yes] [No]
4. Ice packs are properly conditioned [Yes] [No]
5. Use of polythene bag for all vaccines [Yes] [No]
6. All vaccines along with diluents available at session [Yes] [No]
7. Vitamin A available at session [Yes] [No]
8. Any frozen DPT, TT or HepB vial found? [Yes] [No]
9. VVM stage "usable" on OPV and HepB [Yes] [No]
10. All the vaccines at session are within expiry date [Yes] [No]
11. All vaccines have readable labels [Yes] [No]

#### Service delivery and Injection Safety
12. Clean place available for immunization [Yes] [No]
13. Washes hands before beginning the immunization session [Yes] [No]
14. Vaccine is reconstituted correctly just before immunization session [Yes] [No]
15. Time of reconstitution written on vial [Yes] [No]
16. Use of correct diluents for BCG and measles [Yes] [No]
17. Reconstituted vaccines used within four hours of reconstitution [Yes] [No]
18. Use of 0.5 ml AD syringes for all vaccines except BCG [Yes] [No]
19. Use of AD syringes 0.1 ml for BCG [Yes] [No]
20. Correct selection of injection site [Yes] [No]
21. Correct selection of injection route [Yes] [No]
22. Correct technique of giving vaccines (angle of the needle for giving I/D, I/M and S/C injections) [Yes] [No]
23. Correct dose of vaccine given [Yes] [No]
24. Injection surface (if dirty) is cleaned with clean water swab before injecting [Yes] [No]
25. Needle NOT touched with swab or finger before injection [Yes] [No]
26. Correct age of administration of measles vaccine (9-12 months) and up to 5 years to missed children [Yes] [No]
27. Absence of recapping AND bending used syringes [Yes] [No]
28. Hub cutters in use for containing used needles after cutting plastic hub of the used syringes [Yes] [No] [NA]
29. Use of separate needle and syringe for each injection (including reconstitution syringes for each vaccine vial) [Yes] [No]
30. Evidence of maintaining at least 28 days gap between DPT doses [Yes] [No]
31. Correct method of waste collection for disposal [Yes] [No] [NA]
32. No needle stick injuries to ANM during last 3 months [Yes] [No]
Annexure 10: Recognition and Treatment of Anaphylaxis

Anaphylaxis is a very rare (estimated as once every million doses of vaccine given) but severe and potentially fatal allergic reaction. When anaphylaxis does occur, the patient must be diagnosed properly, treated and managed urgently by trained staff and transferred to a hospital setting.

Recognition of anaphylaxis

Anaphylaxis is a severe reaction of rapid onset (usually 5-30 minutes after the injection) characterized by circulatory collapse. The early signs of anaphylaxis are generalized erythema and urticaria with upper and/or lower respiratory tract obstruction. In more severe cases, limpness, pallor, loss of consciousness and hypotension become evident in addition. Vaccinators should be able to recognize the signs and symptoms of anaphylaxis in the box below. In general, the more severe the reaction, the more rapid the onset. Most life-threatening reactions begin within 10 minutes of immunization. Keep the vaccinee under observation for at least 20 minutes after the injection.

Unconsciousness is rarely the sole manifestation of anaphylaxis - it only occurs as a late event in severe cases. A strong central pulse (e.g. carotid) is maintained during a faint, but not in anaphylaxis. Anaphylaxis usually involves multiple body systems. However, symptoms limited to only one body system (e.g., skin itching) can occur, leading to delay in diagnosis. Occasional reports have described reactions where symptoms recur 8 to 12 hours after onset of the original attack and prolonged attacks lasting up to 48 hours.

<table>
<thead>
<tr>
<th>Clinical Progression</th>
<th>Signs and symptoms of anaphylaxis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mild, Early Warning Signs</td>
<td>Itching of the skin, rash and swelling around injection site. Dizziness, general feeling of warmth</td>
</tr>
<tr>
<td></td>
<td>Painless swellings in part of the body e.g., face or mouth. Flushed, itching skin, nasal congestion, sneezing, tears.</td>
</tr>
<tr>
<td></td>
<td>Hoarseness, nausea, vomiting</td>
</tr>
<tr>
<td>Late, Life-threatening Symptoms</td>
<td>Swelling in the throat, difficulty breathing, abdominal pain</td>
</tr>
<tr>
<td>blood</td>
<td>Wheezing, noisy, difficulty breathing, collapse, low pressure, irregular weak pulse</td>
</tr>
</tbody>
</table>

Treatment of anaphylaxis

Once the diagnosis is made, consider the patient as being in a potentially fatal condition, regardless of the severity of the current symptoms. Begin treatment immediately and, at the same time, make plans to transfer the patient swiftly to hospital (if not already in a hospital setting). Adrenaline (epinephrine) stimulates the heart and reverses the spasm in the lung passages, and reduces edema and urticaria, thus countering the anaphylaxis. But this very potent agent can cause irregular heartbeat, heart failure, severe hypertension, and tissue necrosis if used in inappropriate doses.

Each vaccinator who is trained in the treatment of anaphylaxis should have rapid access to an emergency kit with adrenaline, and be familiar with its dosage and administration. The expiry date of the adrenaline should be written on the outside
of the emergency kit and the whole kit should be checked three or four times a year. Adrenaline that has a brown tinge must be discarded.

**Steps in initial management**

If already unconscious, place the patient in the recovery position and ensure the airway is clear.

Assess heart rate and respiratory rate (if the patient has a strong carotid pulse, he/she is probably not suffering from anaphylaxis).

If appropriate, begin cardiopulmonary resuscitation.

Give 1:1000 adrenaline (see below for correct dose for age or weight) by deep intramuscular injection into the opposite limb to that in which the vaccine was given. (Subcutaneous administration is acceptable in mild cases).

**And give an additional half dose around the injection site** (to delay antigen absorption).

If the patient is conscious after the adrenaline is given, place his/her head lower than the feet and keep the patient warm.

Give oxygen by face mask, if available.

Call for professional assistance but never leave the patient alone. Call an ambulance (or arrange other means of transport, after the first injection of adrenaline, or sooner if there are sufficient people available to help you.

If there is no improvement in the patient's condition within 10-20 minutes, of the first injection, repeat the dose of adrenaline up to a maximum of three doses in total.

Recovery from anaphylactic shock is usually rapid after adrenaline.

Record, or get someone to record, vital signs (pulse rate, respiratory rate and blood pressure), as well as time and exact dose of any medication given. Make sure the details accompany the patient when he is transferred. Mark the immunization card clearly so the individual never gets a repeat dose of the offending vaccine. At a suitable moment, explain to parents or relatives the importance of avoiding the vaccine in the future.

Report the occurrence of anaphylaxis to the appropriate officer in the ministry of health by fax or phone when the clinical situation is dealt with.

**Adrenaline dosage:** 1:1000 adrenaline (epinephrine) at a dose of 0.01ml/kg up to a maximum of 0.5 ml injected intramuscularly (or subcutaneously in very mild cases).

If the weight of the patient is unknown, an approximate guide is:

<table>
<thead>
<tr>
<th>Age Group</th>
<th>Dose (ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Less than 2 yrs</td>
<td>0.0625 ml (1/16th of a ml)</td>
</tr>
<tr>
<td>2-5 yrs</td>
<td>0.125 ml (1/8th of a ml)</td>
</tr>
<tr>
<td>6-11 yrs</td>
<td>0.25 ml (1/4 of a ml)</td>
</tr>
<tr>
<td>11+ yrs</td>
<td>0.5 ml (1/2 of a ml)</td>
</tr>
</tbody>
</table>
OPERATIONAL GUIDELINES
for Hepatitis B Vaccine in the
Universal Immunization Programme

Ministry of Health & Family Welfare
Government of India
2009